Response of histiocytoses to imatinib mesylate: Fire to ashes

Journal of Clinical Oncology

Volumn 28, Issue 31, 2010, Pages

  Janku, Filip ^a   Amin, Hesham M ^a   Yang, Dan ^a   Garrido Laguna, Ignacio ^a   Trent, Jonathan C ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; ARG TYROSINE KINASE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ANAMNESIS; ARTICLE; CASE REPORT; ERDHEIM CHESTER DISEASE; FEMALE; GENE MUTATION; HISTIOCYTOSIS X; HUMAN; HUMAN TISSUE; MALE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; BRAIN TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG ADMINISTRATION; DRUG ANTAGONISM; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; ONCOGENE; ORAL DRUG ADMINISTRATION; REMISSION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; ERDHEIM-CHESTER DISEASE; FEMALE; GENES, ABL; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78149267163     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.9073     Document Type: Article

References (21)

1. Beverley PC, Egeler RM, Arceci RJ, et al: The Nikolas Symposia and histiocytosis. Nat Rev Cancer 5:488-494, 2005 (Pubitemid 40791491)
2. Olschewski T, Seegenschmiedt MH: Radiotherapy of Langerhans' cell histiocytosis: Results and implications of a national patterns-of-care study. Strahlenther Onkol 182:629-634, 2006 (Pubitemid 44657648)
3. Gadner H, Grois N, Arico M, et al: A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 138:728-734, 2001 (Pubitemid 32417676)
4. Pardanani A, Phyliky RL, Li CY, et al: 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 78:301-306, 2003 (Pubitemid 36259298)
5. Braiteh F, Kurzrock R, CASE 1: Langerhans cell histiocytosis of the thyroid. J Clin Oncol 24:522-523, 2006 (Pubitemid 46630474)
6. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al: Erdheim-Chester disease: Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 75:157-169, 1996 (Pubitemid 26159212)
7. Egan AJ, Boardman LA, Tazelaar HD, et al: Erdheim-Chester disease: Clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. Am J Surg Pathol 23:17-26, 1999 (Pubitemid 29025237)
8. Gauvrit JY, Oppenheim C, Girot M: Images in cardiovascular medicine: High resolution images obtained with ultrasound and magnetic resonance imaging of pericarotid fibrosis in Erdheim-Chester disease. Circulation 110:e443-e444, 2004
9. Bisceglia M, Cammisa M, Suster S, et al: Erdheim-Chester disease: Clinical and pathologic spectrum of four cases from the Arkadi M. Rywlin slide seminars. Adv Anat Pathol 10:160-171, 2003
10. Myra C, Sloper L, Tighe PJ, et al: Treatment of Erdheim-Chester disease with cladribine: A rational approach. Br J Ophthalmol 88:844-847, 2004 (Pubitemid 38725610)
11. Braiteh F, Boxrud C, Esmaeli B, et al: Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 106:2992-2994, 2005 (Pubitemid 41565890)
12. Appel S, Boehmler AM, Grünebach F, et al: Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 103:538-544, 2004 (Pubitemid 38140084)
13. Montella L, Insabato L, Palmieri G: Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. N Engl J Med 351:1034-1035, 2004 (Pubitemid 39166273)
14. Utikal J, Ugurel S, Kurzen H, et al: Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol 143:736-740, 2007 (Pubitemid 46955732)
15. Gebhardt C, Averbeck M, Paasch U, et al: A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapy. Arch Dermatol 145:571-574, 2009
16. Haroche J, Amoura Z, Charlotte F, et al: Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 111:5413-5415, 2008
17. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
18. Okuda K, Weisberg E, Gilliland DG, et al: ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448, 2001 (Pubitemid 32291492)
19. Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000 (Pubitemid 30618049)
20. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487, 2002 (Pubitemid 34879335)
21. Paulsson J, Sjöblom T, Micke P, et al: Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175:334-341, 2009